Maribavir

Kathryn Dzintars, Pharm.D., BCPS

INDICATIONS

Treatment of post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet in adults and pediatric patients (≥12 years of age and weighing at least 35 kg)
- For any patient to be started on maribavir, use of the Takeda Livtencity PATIENT START FORM is required.

There's more to see -- the rest of this topic is available only to subscribers.

All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.